BioSpace News Archive

Drug Development

Agios Establishes Proof-of-Concept for Mitapivat in Non-transfusion-dependent Thalassemia Based on Preliminary Phase 2 Results

Treatment with Mitapivat Induced Hemoglobin Increase of ≥1.0 g/dL in 7 of 8 Evaluable Patients

December 8, 2019
·
6 min read
Drug Development

Ziopharm Oncology Presents Pre-Clinical Data Validating “Rapid Personalized Manufacture” (RPM) with TCR at the 2019 American Society for Hematology Annual Meeting

Membrane bound IL-15 (mbIL15) improves anti-tumor effect of TCR-modified T cells

December 8, 2019
·
5 min read
Pharm Country

TG Therapeutics Announces Oral Presentation of Umbralisib, Ublituximab and Venetoclax Triple Combination Phase I/II Data in Relapsed/Refractory CLL at the 61st American Society of Hematology Annual Meeting and Exposition

100% overall response rate (ORR) in relapsed/refractory CLL patients treated with U2 (umbralisib + ublituximab) plus venetoclax at cycle 7 (n=13)

December 8, 2019
·
7 min read
Drug Development

Blueprint Medicines Announces Initial Data from Phase 2 PIONEER Trial of Avapritinib in Patients with Indolent Systemic Mastocytosis Showing Activity at All Dose Levels Tested

Plan to initiate screening in registration-enabling portion of PIONEER trial in indolent SM in first half 2020

December 8, 2019
·
14 min read
Pharm Country

First Clinical Data for REGN5458 (BCMAxCD3) Show Positive Preliminary Results in Multiple Myeloma

Regeneron Pharmaceuticals, Inc. announced initial clinical data for REGN5458, a BCMAxCD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma.

December 8, 2019
·
12 min read
Autolus Therapeutics Announces New Data Showcasing Clinical Progress of AUTO3 in B Cell Malignancies

Preliminary data on AUTO3 in DLBCL demonstrate safety and feasibilty of CD19 and CD22 dual targeting CAR T

December 8, 2019
·
7 min read
Drug Development

Oncopeptides Presents Promising Data from the Phase 2 ANCHOR Combination Study in Patients With RRMM at ASH Annual Meeting 2019

Oncopeptides AB will present updated data from the ongoing Phase 2 ANCHOR triple combination study at the ASH Annual Meeting 2019.

December 8, 2019
·
5 min read
Drug Development

Cerevel Therapeutics Announces Phase 1 Results for CVL-865, a Novel α2/3/5-subtype GABAA Positive Allosteric Modulator in Development to Treat Epilepsy

Cerevel Therapeutics announced results of a Phase 1 dose-escalation clinical trial1 evaluating the safety, tolerability and pharmacokinetics of multiple repeated doses of CVL-865 in healthy volunteers.

December 8, 2019
·
6 min read
Drug Development

Stoke Therapeutics Presents Preclinical Data on the Biodistribution, Target Engagement and Safety of STK-001 in Non-Human Primates That Support the Planned Clinical Development of STK-001 for the Treatment of Dravet Syndrome

STK-001 showed distribution throughout the brain after a single intrathecal injection; Target engagement and increased Nav1.1 protein expression were observed throughout the cortex

December 8, 2019
·
8 min read
Biotech Beach

Kura Oncology Reports Clinical and Regulatory Updates for Tipifarnib in Angioimmunoblastic T-Cell Lymphoma

Tipifarnib demonstrates robust and durable activity as a monotherapy in advanced AITL, an aggressive form of T-cell lymphoma

December 8, 2019
·
9 min read